مراجعة
Cutting-Edge: Preclinical and Clinical Development of the First Approved Lag-3 Inhibitor
| العنوان: | Cutting-Edge: Preclinical and Clinical Development of the First Approved Lag-3 Inhibitor |
|---|---|
| المؤلفون: | Chocarro, Luisa, Bocanegra, Ana, Blanco, Ester, Fernández-Rubio, Leticia, Arasanz, Hugo, Echaide, Miriam, Garnica, Maider, Ramos, Pablo, Piñeiro-Hermida, Sergio, Vera, Ruth, Escors, David, Kochan, Grazyna, orcid:0000-0002-3508-0595, orcid:0000-0002-2980-7137, orcid:0000-0001-6838-6702, orcid:0000-0002-7371-1626, orcid:0000-0003-2828-4458 |
| بيانات النشر: | NLM (Medline) |
| سنة النشر: | 2022 |
| مصطلحات موضوعية: | BMS-986016, LAG-3, nivolumab, opdualag, PD-1, relatimab |
| الوصف: | Immune checkpoint inhibitors (ICIs) have revolutionized medical practice in oncology since the FDA approval of the first ICI 11 years ago. In light of this, Lymphocyte-Activation Gene 3 (LAG-3) is one of the most important next-generation immune checkpoint molecules, playing a similar role as Programmed cell Death protein 1 (PD-1) and Cytotoxic T-Lymphocyte Antigen 4 (CTLA-4). 19 LAG-3 targeting molecules are being evaluated at 108 clinical trials which are demonstrating positive results, including promising bispecific molecules targeting LAG-3 simultaneously with other ICIs. Recently, a new dual anti-PD-1 (Nivolumab) and anti-LAG-3 (Relatimab) treatment developed by Bristol Myers Squibb (Opdualag), was approved by the Food and Drug Administration (FDA) as the first LAG-3 blocking antibody combination for unresectable or metastatic melanoma. This novel immunotherapy combination more than doubled median progression-free survival (PFS) when compared to nivolumab monotherapy (10.1 months versus 4.6 months). Here, we analyze the large clinical trial responsible for this historical approval (RELATIVITY-047), and discuss the preclinical and clinical developments that led to its jump into clinical practice. We will also summarize results achieved by other LAG-3 targeting molecules with promising anti-tumor activities currently under clinical development in phases I, I/II, II, and III. Opdualag will boost the entry of more LAG-3 targeting molecules into clinical practice, supporting the accumulating evidence highlighting the pivotal role of LAG-3 in cancer. |
| نوع الوثيقة: | review |
| وصف الملف: | application/pdf |
| اللغة: | English |
| تدمد: | 2073-4409 |
| العلاقة: | info:eu-repo/semantics/altIdentifier/pmid/35954196; info:eu-repo/semantics/altIdentifier/eissn/2073-4409; Cutting-Edge: Preclinical and Clinical Development of the First Approved Lag-3 Inhibitor, 2022, vol. 11, núm. 15; https://investigacion.unirioja.es/documentos/63138b62b8384f133e2d371cTest; urn:issn:2073-4409 |
| DOI: | 10.3390/CELLS11152351 |
| الإتاحة: | https://doi.org/10.3390/CELLS11152351Test https://investigacion.unirioja.es/documentos/63138b62b8384f133e2d371cTest |
| حقوق: | info:eu-repo/semantics/openAccess |
| رقم الانضمام: | edsbas.10288364 |
| قاعدة البيانات: | BASE |
Full Text Finder | تدمد: | 20734409 |
|---|---|
| DOI: | 10.3390/CELLS11152351 |